Increasing off-label use of antipsychotic medications in the United States, 1995-2008.
OBJECTIVE
To evaluate patterns of antipsychotic use. DESIGN, SETTING, AND MEASUREMENTS: We used nationally representative data from the IMS Health National Disease and Therapeutic Index to describe outpatient antipsychotic use. The primary outcome was the volume of visits where antipsychotics were used for specific indications (treatment visits). We also quantified use without U.S. Food and Drug Administration approval (off-label use) and off-label use with compendium data suggesting an uncertain evidence base.


RESULTS
Antipsychotic use increased from 6.2 million (M) treatment visits (95% CI, 5.4-7.0) in 1995 to 16.7 M visits (15.5-18.2) in 2006, then declined to 14.3 M visits (13.0-15.6) by 2008. A shift occurred from typical agents in 1995 (84% of all antipsychotic visits) to atypical agents by 2008 (93%). As they declined, typical medications shifted toward use in schizophrenia (30% in 1995 to 48% 2008). In contrast, use of atypical agents expanded for bipolar affective disorder (10 to 34%), remained stable for depression (12 to 14%), and declined for schizophrenia (56 to 23%). Overall, antipsychotic use for indications without FDA approval increased from 4.4 M visits in 1995 to 9.0 M in 2008. The estimated cost associated with off-label use in 2008 was US$6.0 billion.


CONCLUSIONS
Atypical use has grown far beyond substitution for the now infrequently used typical agents. Antipsychotics are increasingly used for conditions where FDA approval and associated clinical evidence is less certain. Despite the value of innovation, the benefits of widening atypical antipsychotic use should be weighed against their cost, regulatory status, and incomplete nature of available evidence.
Department of Medicine, University of Chicago Hospitals, Chicago, Illinois, USA. galexand@uchicago.edu
G C
GC
Alexander
S A
SA
Gallagher
A
A
Mascola
R M
RM
Moloney
R S
RS
Stafford
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D017277:Drug Approval; D016527:Drug Costs; D011307:Drug Prescriptions; D004363:Drug Utilization / Q000639:trends; D019317:Evidence-Based Medicine; D019983:Guideline Adherence; D019538:Health Care Surveys; D006801:Humans; D008875:Middle Aged; D056687:Off-Label Use / Q000191:economics; D009819:Office Visits / Q000639:trends; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000191:economics / Q000639:trends*; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration; D055815:Young Adult
D014150:Antipsychotic Agents
Am J Psychiatry. 2008 Nov;165(11):1420-31
18794207
J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2):136-41
15098847
Am J Psychiatry. 2006 Apr;163(4):600-10
16585434
Lancet. 1999 Oct 2;354(9185):1202-4
10513728
Schizophr Bull. 2012 Jan;38(1):167-77
20513652
Psychiatr Serv. 2008 May;59(5):507-14
18451006
Br J Psychiatry. 2008 Jun;192(6):406-11
18515889
Health Aff (Millwood). 2005 Jan-Feb;24(1):195-205
15647230
Arch Gen Psychiatry. 2007 Sep;64(9):1032-9
17768268
Arch Intern Med. 2005 Jun 13;165(11):1280-5
15956008
BMJ Clin Evid. 2007 Aug 01;2007:
19454110
J Am Coll Cardiol. 2003 Jan 1;41(1):56-61
12570945
Health Aff (Millwood). 2009 Sep-Oct;28(5):w770-81
19622537
N Engl J Med. 2009 Jan 15;360(3):225-35
19144938
Ann Intern Med. 2007 Jun 5;146(11):775-86
17548409